Systemic Diseases
Aldeyra’s broad product candidate pipeline applies to many diseases that affect diverse aspects of the body. Thus, we are developing product candidates that can be administered orally or by injection to treat disease systemically. Aldeyra is currently developing potential therapies for the treatment of four immune-mediated systemic diseases:
Sjögren-Larsson Syndrome
SLS is a rare systemic disease resulting in ichthyosis (dry and scaly skin), neurological, and retinal disorders. There is currently no FDA-approved therapy for treating severe ichthyosis associated with SLS.
Post-Transplant Lymphoproliferative Disorder
Immune-mediated cancer-like condition characterized by hyperproliferation of immune cells following a solid organ transplant.
Mesothelioma
A rare aggressive cancer surrounding the lungs, approximately 3,000 people are diagnosed each year in the United States.
Ovarian Cancer
Generally diagnosed after significant tumor progression, over 225,000 women have ovarian cancer where a five-year survival is less than 50%.